## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.2% below STRENGTH zone (4.0-10.0%); PEG 14.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.24)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Shorepoint Capital Partners LLC Invests $3.06 Million in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251216T120904 | Somewhat-Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC has initiated a new position in Pfizer Inc. (NYSE:PFE), acquiring 120,211 shares valued at approximately $3.06 million in the third quarter. Other institutional investors like Vanguard, Geode Capital Management, Norges Bank, Northern Trust Corp, and Amundi also significantly adjusted their holdings, bringing total institutional ownership to about 68.36%. Pfizer, with a market cap of around $150.4 billion, recently announced a quarterly dividend of $0.43 per share, yielding approximately 6.5%.

**2. Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open**
- Source: ts2.tech | 20251215T230857 | Neutral | Relevance: 100%
- Pfizer Inc. (NYSE: PFE) saw its stock close up 2.24% on Monday, December 15, 2025, but traded slightly lower after hours as anticipation builds for Tuesday morning's analyst call where 2026 financial guidance is expected. Key drivers for Monday's activity included a new autoimmune research partnership worth up to $890 million and news that the FDA has no current plans for a "black box" warning on COVID-19 vaccines. Investors are now focused on how Pfizer's guidance compares to analyst expectations and its plans for pipeline execution to counter future exclusivity headwinds.

**3. Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025**
- Source: ts2.tech | 20251215T190839 | Neutral | Relevance: 100%
- Pfizer (NYSE: PFE) is under investor scrutiny on December 15, 2025, driven by a new collaboration with Adaptive Biotechnologies, a crucial 2026 guidance event set for December 16, and ongoing debates about its pipeline and value. The stock is trading around $26.36, near its 52-week high, with analysts maintaining a "Hold" stance and a significant 6.5% dividend yield attracting income-focused investors. The upcoming guidance call is expected to provide clarity on cost cuts, post-COVID revenue, and the integration of new obesity-focused deals.

**4. Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)**
- Source: ts2.tech | 20251215T130835 | Neutral | Relevance: 100%
- Pfizer (PFE) stock is trading around $25.85, ahead of its 2026 guidance call set for Dec. 16. The company recently declared a $0.43 quarterly dividend, announced a licensing agreement for an early-stage GLP-1 obesity candidate with YaoPharma, and continues to manage cost-cutting initiatives and pipeline momentum in oncology. Investors are closely watching for clarity on post-COVID growth, the impact of new acquisitions, and the company's strategy amid evolving regulatory landscapes, such as potential "black box" warnings for COVID-19 vaccines.

**5. 47,996 Shares in Pfizer Inc. $PFE Acquired by MASTERINVEST Kapitalanlage GmbH**
- Source: MarketBeat | 20251215T120848 | Neutral | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH recently acquired 47,996 shares of Pfizer Inc. ($PFE) in the second quarter, valued at approximately $1.163 million. This purchase is part of broader institutional investment activity in Pfizer, with other major investors like Vanguard Group Inc. and Geode Capital Management LLC also increasing their stakes. Analysts have issued a consensus "Hold" rating for Pfizer, with a target price of $28.33.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $28 | $29 | -3% |
| 2025-12-12 | Morgan Stanley | $28 | $32 | -12% |
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 14.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 14.22 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $145.2B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 14.22 |
| Forward P/E | 8.4 |
| Current P/E | 8.2 |
| YoY Growth | -2.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.1% to 0.2% (+1.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.8pp (needs >4.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 51. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -MLH (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.19% (CS: 44) | Neutral |
| RSI_14 | 50.8 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.017x | Above |
| vs SMA200 | 1.041x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.54
- **Stop Loss:** $24.24 (5.1% risk)
- **Target:** $26.84 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 769
- **Position Value:** $19,640.26
- **Portfolio %:** 19.64%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*